Tag: COVID vaccine

Indian study debunks heart attack risk linked to COVID-19 vaccines

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

There is no association between the COVID-19 vaccines used in India — Covishield and Covaxin — and an increase in the risk of heart attacks, according to an observational study that emphasises the protective effect of the jabs.

The research, published recently in the journal PLOS One, determined the impact of COVID-19 vaccination on mortality following acute myocardial infarction (AMI) or heart attack.

The retrospective study used data from 1,578 people admitted to GB Pant Hospital in Delhi between August 2021 and August 2022. As many as 1,086 (68.8 percent) were vaccinated against COVID-19 while 492 (31.2 percent) were unvaccinated.

Among the vaccinated group, 1,047 (96 percent) had received two doses of the vaccine while 39 (4 percent) had received only a single dose.

“Our study found that vaccines used in India are safe. There was no association of vaccination in India with heart attack. In fact, the study found that there were less chances of death after heart attack in vaccinated individuals,” Mohit Gupta, who led the study, from GB Pant Hospital, told PTI.

The adverse effects (AEs) of COVID-19 vaccines have mostly been mild, transient and self-limiting. However, concerns have been raised regarding the cardiovascular adverse effects of these vaccines.

Any side effect can have catastrophic effects, especially in large densely populated countries such as India, the authors noted.

In all the enrolled patients, data regarding the patient’s vaccination status including details on the type of vaccine, date of vaccination and adverse effects were obtained.

The researchers found that the analysis did not show a specific clustering of AMI at any particular time post-vaccination, suggesting there was no significant association between COVID-19 jabs and heart attacks.

On 30-day follow-up, all-cause mortality occurred in 201 (12.7 percent) patients with adjusted odds of mortality being significantly lower in the vaccinated group.

Similarly, at six months of follow-up, the vaccinated AMI group had lower odds of mortality as compared to the non-vaccinated group.

COVID-19 vaccines showed a decrease in all-cause mortality at 30 days and six months following AMI, according to the study.

However, increasing age, diabetics and smokers had a higher risk of 30-day mortality, the researchers said.

“Findings of our study showed that the 30-day and six-month all-cause mortality risk was significantly lower in the vaccinated subjects as compared to the unvaccinated population,” the authors of the study said.

This study is the first to be conducted among a larger population of AMI patients which has shown the COVID-19 vaccine to be not only safe but also have a protective effect in terms of reduction of all-cause mortality both on short term as well as at six months of follow-up, the authors of the study said.

They noted some limitations, saying that this was a single-centre retrospective study, and the findings need to be validated in further larger studies from different ethnic groups.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

FDA votes for COVID vaccines targeting XBB variants, Pfizer aims for July production

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

Pfizer Inc. has said that it can produce COVID-19 vaccines that target the XBB.1.5 strain by the end of July, provided government regulators recommend it. The pharmaceutical giant, in collaboration with BioNTech SE, also stated that the development of a vaccine for the XBB.1.16 strain would take a bit longer, with an estimated delivery time of August.

These announcements were made by Kena Swanson, Pfizer’s vice president for viral vaccines, during a meeting of the US Food and Drug Administration’s vaccine advisers on Thursday.

The committee also unanimously voted for monovalent COVID shots in the fall and winter targeting the XBB variants, which are now the dominant strains of the SARS-CoV-2 virus in the world.

Why do we need updated vaccines?

Initially designed to combat the original strain of COVID-19 that originated in Wuhan, China, vaccines have undergone adaptations to address emerging variants.

Updated vaccines are necessary to address the ongoing evolution of the SARS-CoV-2 virus and its emerging variants. As the virus mutates over time, new strains with different characteristics can emerge, potentially rendering existing vaccines less effective.

ALSO READ | New study reveals overactive inflammation as potential cause of long COVID

By developing updated vaccines that specifically target these new strains, we can enhance protection against the latest variants, reduce the likelihood of breakthrough infections and maintain the effectiveness of vaccination campaigns in mitigating the spread of the virus and preventing severe illness.

Pfizer’s presentation at the FDA meeting indicated that targeting a single strain of XBB, a highly contagious version of the omicron variant, would be the most effective approach based on the latest data.

In line with these findings, a panel from the World Health Organization recommended in May that vaccine manufacturers focus on developing shots for the XBB.1 strains. Moderna Inc. also expressed its ability to supply a new vaccine later this year, supporting the WHO’s recommendation.

ALSO READ | 3 infections, 1 test | NIV’s test kit for Influenza A, Influenza B, COVID-19 up for grabs

Novavax, a biotechnology company, shared its plans to have a vaccine targeting the XBB.1.5 strain ready for distribution in the fall. However, any potential delay in production may occur if the FDA advises a different formulation

For instance, vaccines directed at the XBB.1.16 strain would likely require an additional eight weeks of development, as explained by Filip Dubovsky, Novavax’s president of research and development, during the meeting.

With agency inputs.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

COVID-19 | India reports decline in active cases, Mexico develops vaccine after 2 years

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

India has reported a decrease in the number of active coronavirus cases, which currently stands at 36,244, down from 40,177. The health ministry’s latest data, updated on Thursday, shows that the country recorded 3,962 new infections in the past 24 hours.

The national daily positivity rate now stands at 2.17 percent.

Despite the decrease in active cases, the death toll has increased to 5,31,606, with 22 deaths reported, including seven reconciled by Kerala, as per the ministry’s update at 8 am. The total COVID-19 case tally in India is 44.9 million.

ALSO READ | Pfizer’s Q1 results beat estimates despite sharp COVID-19 vaccine sales drop

The active cases currently comprise only 0.08 percent of the total infections, and the national COVID-19 recovery rate has been recorded at an impressive 98.73 percent, the ministry said.

Furthermore, 4,43,92,828 people have recovered from the disease so far, and the case fatality rate stands at 1.18 percent.

Delhi reported 272 new COVID-19 cases with a positivity rate of 8.39 percent and one death, the local health department recorded on Thursday.

ALSO READ | World needs better COVID vaccines, says CEPI CEO

The ministry’s website also reports that 2.2 billion doses of the coronavirus vaccine have been administered across the country under the nationwide vaccination drive.

According to the Press Information Bureau, 2,363 doses of the vaccine were administered in the past 24 hours.

Mexico develops own COVID-19 vaccine called Patria

Mexico has finally developed its own COVID-19 vaccine, called Patria or Motherland, more than two years after inoculations from the US, Europe and China were rolled out, AP reported.

The vaccine is a joint effort between the government and a Mexican company, Avimex, which previously worked on animal vaccines.

Vaccine uptake in Mexico dropped in late 2022 and 2023, and Mexico still has millions of doses of the Abdala vaccine it bought from Cuba.

ALSO READ | India completes 2 years of COVID vaccination — the success story so far

Patria will be used as a booster shot, though Dr Fidel Alejandro Sánchez, a council member of Mexican researchers, has doubts about using the vaccine, which was designed two years ago, against currently circulating virus strains.

“It is like reading yesterday’s newspaper,” Sánchez said. “It makes no sense to use it as a booster when it wasn’t designed for that.”

It is unclear whether the government medical approval agency has formally authorized Patria.

Mexico’s official death toll of test-confirmed COVID-19 deaths stands at almost 334,000, but testing was scarce in the early days of the pandemic and the government’s own review of death certificates shows more than 505,000 deaths where COVID-19 was listed as a cause of contributing cause of death.

With agency inputs.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Pfizer’s Q1 results beat estimates despite sharp COVID-19 vaccine sales drop

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

Pfizer on Tuesday, May 2, announced its first quarter results, which exceeded Wall Street’s expectations, despite a sharp decline in sales of its flagship COVID-19 vaccine. In the first three months of 2021, revenue from Pfizer’s Comirnaty vaccine plummeted by 77 percent, generating only $3 billion in sales, compared to over $13 billion in the same period last year.

The drugmaker saw a significant decline in net income in the first quarter, with a 30 percent decrease amounting to $5.54 billion, with adjusted results totalling $1.23 per share. The company’s total revenue also decreased by 29 percent to $18.3 billion.

Nevertheless, it beat the Street expectations.

According to FactSet, a financial data and software company, analysts predicted that Pfizer would report earnings of 98 cents per share on $16.61 billion in sales.

Many industry experts anticipated the decline in sales of Pfizer, as the company transitions from supplying governments through large contracts to selling the vaccine in the commercial market this year. As a result of this shift, Pfizer has forecast a 64 percent drop in Comirnaty sales this year and a 58 percent decline in revenue from its leading COVID-19 treatment, Paxlovid.

In the first quarter, sales for Paxlovid surpassed $4 billion, primarily due to the timing of a final delivery for Pfizer’s US government contract.

Also read: Ambuja Cements Q4 profit rises marginally to Rs 502 crore; co announces final dividend

Pfizer expects commercial sales for both to kick in later this year, after leftover government inventory is absorbed.

Over the past several quarters, both the vaccine and treatment for COVID-19 have generated substantial revenue for Pfizer. However, in addition to these products, Pfizer also produces cancer treatments and other vaccines.

In the first quarter, revenue for Pfizer’s Prevnar vaccine, which helps prevent pneumonia and related bacterial diseases, grew by 4 percent to reach $1.6 billion.

Also read: UCO Bank Q4 results: Net profit zooms 86% to Rs 581 crore as bad loans decline

Pfizer reaffirmed its estimate for full-year earnings to be between $3.25-3.45 per share.

In January, when Pfizer first released this forecast, it was initially below what Wall Street had anticipated.

Also read: Titan Q4 Result Preview: Operating margin, June quarter outlook key to track

As per FactSet, analysts have revised their earnings estimate for Pfizer to $3.39 per share.

As a result, shares of Pfizer, which is headquartered in New York, started to rise in early-morning trading.

With inputs from agency

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

COVID-19 Highlights: Covovax to be available as booster on CoWIN soon, to cost Rs 225 per dose

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

India reported 5,880 new COVID-19 cases and 12 more deaths in the last 24 hours, according to the data released by the Union health ministry early Monday. The active COVID-19 caseload also rose to 35,199, constituting 0.08 percent of the total coronavirus cases in the country. A mock drill will be conducted at hospitals across the country on Monday and Tuesday to take stock of the preparedness amid the coronavirus spike. Several states and Union Territories including Kerala and Puducherry have made masks mandatory in public amid COVID spike.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

‘India was the only country..’: PM Modi lauds CoWin game-changer in ‘The Vial – India’s Vaccine Story’

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

History TV18’s 60-minute documentary, titled “The Vial – India’s Vaccine Story,” is the first to feature Prime Minister Narendra Modi where he speaks in detail about India’s victory over the Covid-19 pandemic.

The mammoth task of vaccinating a billion-plus population, many in far-flung areas and rough terrain, against Covid-19 was accomplished primarily on the back of the game-changing CoWIN platform launched on January 16, 2021.

The interface has become so successful that the government is now planning to repurpose the CoWIN platform for India’s Universal Immunisation Programme and other national health programmes while continuing with its current function of recording Covid-19 vaccination and issuing certificates.

Also Read: ‘My way of paying tribute’, says Manoj Bajpayee on voicing History TV18’s Covid-19 vaccine documentary

In History TV18’s documentary titled “The Vial – India’s Vaccine Story”, PM Modi spoke about the role played by CoWin in India’s fight against Covid-19. “India is the only country where thanks to a platform like CoWIN, people could see where they could get vaccinated, what time they had to reach the vaccination centre so as not to overcrowd in queues. It gave details of when to take the second shot. Technology was ably used for it,” he said.

Narrated by renowned actor Manoj Bajpayee, “The Vial” brings to life the inside story of what went into producing the Covid-19 vaccine vial, unfolding the story behind India’s success in developing, manufacturing and delivering the Covid-19 vaccine in unprecedented timelines.

In the documentary, Dr RS Sharma, CEO, National Health Authority, said, “Unless it is done in a manner which is transparent, where the VVIP also looks at the same dashboard and platform as the poor man… that kind of information symmetry is very important.”

Dr Sharma had earlier said that around 50 countries, including Canada, Mexico, Nigeria and Panama, have shown interest in having a CoWIN-like system to run their vaccination drive and that India is ready to share the open source software free of cost.CoWIN has also been lauded by Bill & Melinda Gates Foundation CEO Mark Suzman.

Also Read: Not just tough terrain, frontline workers fought mindsets for Covid jab | History TV18 Documentary

“The CoWIN app that was used is a great global model that we think has potential to show how other countries, including in Africa, could take and develop their own interventions for, in this case, health,” he said.

Inside “The Vial”

The 60-minute documentary is the first to feature PM Modi where he speaks in detail about India’s victory over the coronavirus pandemic. “The Vial” also chronicles the development of the Covishield vaccine — from isolation of the strain at Pune’s National Institute of Virology to manufacturing billions of vials of two of the world’s most effective vaccine candidates in record time to cater to the country’s massive population.

It takes a closer look at some of the case studies that put the spotlight on the determination of the Indian government and health workers in making vaccines accessible to people even in the remotest areas, braving harsh terrain and landscapes.

Also Read: ‘The Vial’ trailer out: Manoj Bajpayee narrates History TV18’s documentary on India’s COVID-19 vaccine journey

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

World needs better COVID vaccines, says CEPI CEO

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

As the world continues to battle the COVID-19 pandemic, several developments and challenges have come to light. Dr Richard Hatchett, the CEO of the Coalition for Epidemic Preparedness Innovations (CEPI), has pointed out that while there has been a decrease in commercial demand for COVID-19 vaccines, the need for better vaccines still remains.

CEPI is a global partnership that is focused on developing vaccines against emerging infectious diseases.

Dr Hatchett said, “Our organization CEPI thinks – we continue to need better vaccines, vaccines that can prevent transmission, and ideally protect against not just the COVID that we have now, but that evolves in the future.”

Talking about commercial demand Dr Hatchett mentioned that commercial demand for COVID vaccines has also declined.

He added, “Drivers for vaccine development now I think is going to require continued public sector investment. We have got a program that we are funding, where we have allocated around $230 million US to develop what we are calling broadly protective coronavirus vaccines. These will be vaccines that protect against COVID, but also against SARS and MERS and other coronaviruses.”

Read Here | Adani Group crisis: Veteran banker KV Kamath says ‘no single group carves out destiny of the nation’

Dr Hatchett has also highlighted the importance of understanding the nature of the virus and how it can mutate. He believes current vaccines are really good at preventing severe disease and death. Still, they are not preventing transmission and every new case of COVID presents an opportunity for the virus to mutate and evolve.

He said, “We are seeing continued evolution of the virus so we have to update the vaccines. I think that’s what we are anticipating likely to be the case with COVID as we continue to live with this virus in future years.”

Watch the video for more.

Also Read | Manish Sisodia Latest Updates: Delhi court sends Deputy CM to CBI custody till March 4

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

US proposes once-a-year COVID shots for most Americans

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

US health officials want to make COVID-19 vaccinations more like the annual flu shot.

The Food and Drug Administration on Monday proposed a simplified approach for future vaccination efforts, allowing most adults and children to get a once-a-year shot to protect against the mutating virus.

This means Americans would no longer have to keep track of how many shots they’ve received or how many months it’s been since their last booster.

The proposal comes as boosters have become a hard sell. While more than 80% of the U.S. population has had at least one vaccine dose, only 16% of those eligible have received the latest boosters authorized in August.

The FDA will ask its panel of outside vaccine experts to weigh in at a meeting Thursday. The agency is expected to take their advice into consideration while deciding future vaccine requirements for manufacturers.

In documents posted online, FDA scientists say many Americans now have “sufficient preexisting immunity” against the coronavirus because of vaccination, infection or a combination of the two. That baseline of protection should be enough to move to an annual booster against the latest strains in circulation and make COVID-19 vaccinations more like the yearly flu shot, according to the agency.

For adults with weakened immune systems and very small children, a two-dose combination may be needed for protection. FDA scientists and vaccine companies would study vaccination, infection rates and other data to decide who should receive a single shot versus a two-dose series.

FDA will also ask its panel to vote on whether all vaccines should target the same strains. That step would be needed to make the shots interchangeable, doing away with the current complicated system of primary vaccinations and boosters.

The initial shots from Pfizer and Moderna — called the primary series — target the strain of the virus that first emerged in 2020 and quickly swept across the world. The updated boosters launched last fall were also tweaked to target omicron relatives that had been dominant.

Under FDA’s proposal, the agency, independent experts and manufacturers would decide annually on which strains to target by the early summer, allowing several months to produce and launch updated shots before the fall. That’s roughly the same approach long used to select the strains for the annual flu shot.

Ultimately, FDA officials say moving to an annual schedule would make it easier to promote future vaccination campaigns, which could ultimately boost vaccination rates nationwide.

The original two-dose COVID shots have offered strong protection against severe disease and death no matter the variant, but protection against mild infection wanes. Experts continue to debate whether the latest round of boosters significantly enhanced protection, particularly for younger, healthy Americans.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

DCGI approves market authorisation for Covovax as COVID booster dose

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

The Drug Controller General of India (DCGI ) has approved market authorisation to COVID-19 vaccine Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin, official sources said on Monday.

The DCGI’s approval came following recommendation by the Subject Expert Committee of the Central Drugs Standard Control Organisation (CDSCO).

Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute of India (SII), had recently written to the DCGI for the approval of Covovax heterologous booster dose for those aged 18 years and above in view of escalating COVID-19 pandemic situation in some countries, an official source had said.

“The Subject Expert Committee of the CDSCO on Wednesday deliberated on the issue and had recommended for market authorisation of Covid jab Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin,” an official source said.

The DCGI had approved Covovax for restricted use in emergency situations in adults on December 28, 2021, in the 12-17 age group on March 9, 2022, and in children aged 7- 11 years on June 28 last year subject to certain conditions.

Covovax is manufactured through technology transfer from Novavax. It has been approved by the European Medicines Agency for conditional marketing authorisation. It was granted emergency-use listing by the World Health Organization (WHO) on December 17, 2021.

In August 2020, US-based vaccine maker Novavax Inc. had announced a licence agreement with the SII for the development and commercialization of NVX-CoV2373, its COVID-19 vaccine candidate in India and low-and-middle-income countries.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

India completes 2 years of COVID vaccination — the success story so far

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

India completed two years of its vaccination drive today, January 16. Over 220.16 crore doses of the COVID-19 vaccine have been administered in the two years since its launch. With its recent launch of iNCOVACC, its first nasal vaccine, India has been making strides in its battle against COVID-19.

Union Health Minister Mansukh Mandaviya took to Twitter to congratulate people on the country’s achievement of having the “world’s largest and most successful vaccination drive.” He saluted the efforts of doctors and other healthcare workers on the front line who made this achievement possible.

Also read: Imports of COVID-19 vaccines exempted from customs duty till March 31

According to the Ministry of Health and Family Welfare’s website, total vaccinations are at 2,20,17,06,017 as of 8 am on January 16, 2023. Over 3,900 of these were administered in the past 24 hours.

By this time last year, India had administered 156.76 crore doses. Since January 16, 2022, the government has administered 63.4 crore doses, around 40.44 percent of what it did in the first year.

The drive was rolled out on January 16, 2021, with healthcare workers getting inoculated in the first phase. Vaccination of frontline workers started from February 2, 2021. The next phase of the COVID-19 vaccination commenced from March 1, 2021, for people over 60 years of age and those aged 45 and above with specific comorbid conditions.

Vaccination of all Indians aged over 45 began from April 1, 2021. The government then decided to expand the ambit of the inoculation drive by allowing everyone above 18 to be vaccinated from May 1, 2021.

The country set a record on September 17, 2021 when it administered 2.5 crore doses.

The next phase of COVID-19 vaccination commenced from January 3, 2022, for adolescents in the age group of 15-18 years.

The government approved booster doses for everyone over the age of 18 on April 10, 2022.

It crossed the landmark of 200 crore doses as a part of the nationwide vaccination drive on July 17, 2022.

“Proud of those who contributed to making India’s vaccination drive unparalleled in scale and speed,” Prime Minister Narendra Modi had tweeted then.

The ministry reported 2,119 active cases and a grand total of 4,41,48,309 as of 8 am, January 16.

Also read: COVID-19 vaccines effective against Omicron sub-variant BF.7, says Health Minister Mansukh Mandaviya

According to a vaccine tracker developed by the Indian Council of Medical Research, more than 95.86 percent of India’s adult population had taken at least one dose of the COVID-19 vaccine.

Minister of Parliamentary Affairs Pralhad Joshi joined in on the celebrations and praised Prime Minister Narendra Modi for leading India’s fight against the “menace of this pandemic.” Commerce and Industry Minister Piyush Goyal also lauded the milestone which he said marks “India’s exemplary resilience.”

With agency inputs.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow